Company profile: Remedy Plan
1.1 - Company Overview
Company description
- Provider of pre-clinical cancer therapeutics developing first-in-class small molecule drugs that differentiate cancer cells, including RPT1G, a clinical candidate targeting NAMPT for solid and hematological malignancies. Offers NAMPT programs in oncology, autoimmune, and obesity, and a proprietary high-throughput phenotypic drug screening platform targeting critical pathways in cancer stem cells.
Products and services
- Drug Screening Platform: High-throughput phenotypic platform that identifies and optimizes novel small-molecule drug candidates targeting critical signaling pathways in cancer stem cells
- RPT1G: First-in-class small molecule clinical drug candidate targeting NAMPT for solid and hematological malignancies, employing a unique mechanism that avoids on-target toxicity
- NAMPT - Oncology: Target-specific program developing NAMPT inhibitors for cancer treatment, leveraging RPT1G’s unique properties to advance candidates for solid and hematological malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Remedy Plan
Affymetrix
HQ: United States
Website
- Description: Provider of innovative technologies enabling multiplex and parallel analysis of biological systems at the cell, protein, and gene level, facilitating rapid translation of results into biology. Offerings include GeneChip microarrays for gene expression and genetic variation analysis, GeneTitan for high-throughput microarray processing, Axiom genotyping solutions, and CytoScan cytogenetic microarrays for detecting chromosomal abnormalities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affymetrix company profile →
Bruker
HQ: United States
Website
- Description: Provider of analytical and medical instruments covering NMR, ESR, FT-IR and X-ray spectroscopy. MALDI Imaging to visualize molecular distribution in tissue sections; neofleX MALDI-TOF/TOF benchtop MS for protein and peptide analysis; Q6 NEWTON optical emission spectrometer for precise metal and alloy composition; BEAM FT-NIR for real-time process control of solid and semi-solid materials; and Dektak Pro profilometer for semiconductor surfaces.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bruker company profile →
LI-COR
HQ: United States
Website
- Description: Provider of highly engineered instrumentation systems, analysis software, and reagents for environmental and plant research, gas analysis, agriculture, drug discovery, protein research, and small animal imaging; used in more than 100 countries and on the International Space Station.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LI-COR company profile →
Biomatrica
HQ: United States
Website
- Description: Provider of biostability technologies to stabilize, process, store and ship biological samples at room temperature, preserving complex biological samples and assays based on the principles of anhydrobiosis; products include LBgard Blood Tubes for room‑temperature stabilization of blood samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomatrica company profile →
Isobionics
HQ: The Netherlands
Website
- Description: Provider of isoprenoid-based flavor and fragrance ingredients produced via a proprietary biotechnology process for the food, beverage, flavor and fragrance markets, delivering higher quality and purity at lower production cost. Portfolio includes Natural Nootkatone, beta-Caryophyllene, Valencene, (-)-alpha-Bisabolol, alpha-Bisabolene, and beta-Bisabolene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Isobionics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Remedy Plan
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Remedy Plan
2.2 - Growth funds investing in similar companies to Remedy Plan
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Remedy Plan
4.2 - Public trading comparable groups for Remedy Plan
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →